In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. research hub

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

This study is testing new combinations of medicines (Retifanlimab, INCAGN02385, and INCAGN02390) for people with advanced head and neck cancer that has a specific marker called PD-L1. It aims to see if these combinations can stop the cancer from growing for longer.